Does roxithromycin prevent death and re-infarction in patients with acute non-Q-wave coronary syndromes?
In patients with acute non-Q-wave coronary syndromes, roxithromycin may provide clinical benefit by preventing death and re-infarction at 6 months.
In this pilot trial, roxithromycin appears to extend the clinical benefit of preventing death and re-infarction for at least 6 months after initial treatment.
Enrique Gurfinkel (Fri,) studied this question.